Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
GRPH Graphite Bio
2.070-0.110-5.05%
Close
02/03 16:00 ET
2.0700.0000.00%
Post Mkt Price 02/03 16:35 ET
High
2.205
Open
2.150
Turnover
116.78K
Low
2.020
Pre Close
2.180
Volume
55.49K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Morgan Stanley Adjusts Price Target on Graphite Bio to $3 From $6, Maintains Equal-Weight Rating
11:47 AM EST, 02/03/2023 (MT Newswires) -- (MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may co
Graphite Bio Is Maintained at Equal-Weight by Morgan Stanley
Graphite Bio Price Target Cut to $3.00/Share From $6.00 by Morgan Stanley
Morgan Stanley Maintains Equal-Weight on Graphite Bio, Lowers Price Target to $3
Morgan Stanley analyst Jeffrey Hung maintains Graphite Bio (NASDAQ:GRPH) with a Equal-Weight and lowers the price target from $6 to $3.
BTIG Research Lowers Graphite Bio (NASDAQ:GRPH) to Neutral
BTIG Research downgraded shares of Graphite Bio (NASDAQ:GRPH – Get Rating) from a buy rating to a neutral rating in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports.
Benzinga's Top Ratings Upgrades, Downgrades For January 25, 2023
UpgradesAccording to B of A Securities, the prior rating for Hannon Armstrong Sustainable Infrastructure Capital Inc (NYSE:HASI) was changed from Underperform to Neutral. In the third quarter, Hannon
Expert Ratings for Graphite Bio
Analysts have provided the following ratings for Graphite Bio (NASDAQ:GRPH) within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings00400Last 30D000001M Ago00400
Graphite Bio Cut to Neutral From Buy by BTIG
Graphite Bio Cut to Neutral From Buy by BTIG
BTIG Downgrades Graphite Bio to Neutral
BTIG analyst Yun Zhong downgrades Graphite Bio from Buy to Neutral.
Graphite Bio Downgraded to Neutral From Buy at BTIG
Company Overview
More
Graphite Bio, Inc. operates as a clinical-stage gene editing company. It focuses on therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo in June 2017 and is headquartered in South San Francisco, CA.
CEO： Dr. Joshua Lehrer-Graiwer, M.D.
Market： NASDAQ
Listing Date： 06/25/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet